Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | USP8 | P40818 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373794 | 0.91 | P2RX7 (0.42) | P2RX7MEN1KMT2AP2RY1KCNA3 | |
| SCHEMBL3376075 | 0.90 | P2RX7 (0.42) | P2RX7MEN1KMT2AP2RY1KCNA3 | |
| SCHEMBL3376467 | 0.89 | P2RX7 (0.42) | P2RX7MEN1KMT2AP2RY1KCNA3 | |
| SCHEMBL3777258 | 0.84 | MEN1 (0.46) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL3777973 | 0.83 | ALDH1A1 (0.46) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL14541417 | 0.79 | P2RX7 (0.42) | P2RX7P2RY1USP2USP8ALDH1A1 | |
| SCHEMBL3376875 | 0.79 | MEN1 (0.42) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL13068788 | 0.79 | MEN1 (0.41) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL1970190 | 0.78 | SCN9A (0.40) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL13068786 | 0.77 | ALDH1A1 (0.43) | P2RX7MEN1KMT2AP2RY1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937659-B1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | disclosed |
| US-7683181-B2 | Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-03-23 | — | — | US | disclosed |
| US-7683181-B2 | Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-03-23 | — | — | US | disclosed |
| US-20080280959-A1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | US | disclosed |
| US-20080280959-A1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | US | disclosed |
| EP-1937659-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039173-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039173-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280959-A1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF | PPARD, GPR119, PPARG | P2RX7 360/4885MEN1 4660/4885KMT2A 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.